Results: 1-25 | 26-50 | 51-57

Table of contents of journal: *Cancer biotherapy & radiopharmaceuticals

Results: 1-25/57

Authors: OLDHAM RK
Citation: Rk. Oldham, INTERLEUKIN-2 - DOSE, SCHEDULE AND ROUTE, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(6), 1997, pp. 363-364

Authors: DELIMA M AMATO RJ JACKSON A TU SM BANKS M FINN L ELLERHORST J
Citation: M. Delima et al., PHASE I-II STUDY OF GAMMA-INTERFERON AND 5-FLUOROURACIL FOR PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(6), 1997, pp. 365-370

Authors: ARINAGA S UEO H GO H AKIYOSHI T
Citation: S. Arinaga et al., NEOADJUVANT CHEMOIMMUNOTHERAPY WITH CISPLATIN AND LOW-DOSE INTERLEUKIN-2 FOR LOCALLY ADVANCED ESOPHAGEAL-CARCINOMA, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(6), 1997, pp. 371-374

Authors: SAFAVY A KHAZAELI MB MAYO MS BUCHSBAUM DJ
Citation: A. Safavy et al., SYNTHESIS, RE-188 LABELING AND BIODISTRIBUTION STUDIES OF A PHENOLIC ESTER DERIVATIVE OF TRISUCCIN, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(6), 1997, pp. 375-384

Authors: CONTASTA I PELLEGRINI P BERGHELLA AM DELBEATO T CANOSSI A MACCARONE D PAPOLA F ADORNO D CASCIANI CU
Citation: I. Contasta et al., IMMUNOLOGICAL IMPLICATIONS OF ALTERATIONS IN THE C-KI-RAS AND P53 GENES IN THE STEPWISE PROGRESSION OF COLORECTAL-CANCER - INDICATIONS FOR THE IMPROVEMENT OF PROGNOSIS, BIOTHERAPY TREATMENT AND TUMOR BIOLOGY UNDERSTANDING, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(6), 1997, pp. 385-393

Authors: NILSSON S ESSAND M LOGDAHL P LARSON A NORDGREN H JUHLIN C
Citation: S. Nilsson et al., E4, A NEW MONOCLONAL-ANTIBODY IDENTIFYING A HUMAN PROSTATIC CELL-SURFACE ANTIGEN, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(6), 1997, pp. 395-403

Authors: KAMEI H KOIDE T HASHIMOTO Y KOJIMA T UMEDA T HASEGAWA M
Citation: H. Kamei et al., TUMOR-CELL GROWTH-INHIBITING EFFECT OF MELANOIDINS EXTRACTED FROM MISO AND SOY-SAUCE, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(6), 1997, pp. 405-409

Citation: ABSTRACTS FROM THE 3RD INTERNATIONAL-CONFERENCE ON PINEAL-GLAND AND CANCER - UNIVERSITY-OF-TUBINGEN, OCTOBER 2-5, 1997, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(6), 1997, pp. 412-433

Authors: OLDHAM RK
Citation: Rk. Oldham, CANCER BIOTHERAPY - WHEN, WHY AND HOW LONG, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(5), 1997, pp. 295-296

Authors: DELBEATO T BERGHELLA AM PELLEGRINI P DOMENICO A CASCIANI CU
Citation: T. Delbeato et al., THE ROLE OF THE SOLUBLE CD30 SERUM LEVEL IN COLORECTAL-CANCER - A POSSIBLE MARKER FOR A PATIENT SUBSET WHICH COULD BENEFIT FROM IL-2 BIOTHERAPY, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(5), 1997, pp. 297-304

Authors: SLAVINCHIORINI DC KASHMIRI SVS LEE HS MILENIC DE POOLE DJ BERNON E SCHLOM J HAND PH
Citation: Dc. Slavinchiorini et al., A CDR-GRAFTED (HUMANIZED) DOMAIN-DELETED ANTITUMOR ANTIBODY, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(5), 1997, pp. 305-316

Authors: PERNG YP LIN CC PERNG IM SHEN YC CHUANG CK LIAO SK
Citation: Yp. Perng et al., CULTURE-MEDIUM INDUCED MORPHOLOGICAL-CHANGES OF MELANOMA-CELLS ASSOCIATED WITH CHANGE IN SENSITIVITY TO LYSIS BY LYMPHOKINE-ACTIVATED KILLER-CELLS, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(5), 1997, pp. 317-331

Authors: KUMAR R EUE I DONG ZY KILLION JJ FIDLER IJ
Citation: R. Kumar et al., EXPRESSION OF INFLAMMATORY CYTOKINES BY MURINE MACROPHAGES ACTIVATED WITH A NEW SYNTHETIC LIPOPEPTIDE JT3002, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(5), 1997, pp. 333-340

Authors: KAMEI H HASHIMOTO Y KOIDE T KOJIMA T HASEGAWA M UMEDA T
Citation: H. Kamei et al., DIRECT TUMOR-GROWTH SUPPRESSIVE EFFECT OF MELANOIDIN EXTRACTED FROM IMMUNOMODULATOR-PSK, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(5), 1997, pp. 341-344

Authors: THEODORE TR VANZANDT RL CARPENTER RH
Citation: Tr. Theodore et al., PILOT ASCENDING DOSE TOLERANCE STUDY OF PARENTERALLY ADMINISTERED 4-(2 HYDROXYETHYL)-1-PIPERAZINE ETHANE SULFONIC-ACID (TVZ-7) IN DOGS, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(5), 1997, pp. 345-349

Authors: THEODORE TR VANZANDT RL CARPENTER RH
Citation: Tr. Theodore et al., PRELIMINARY EVALUATION OF A FIXED-DOSE OF ZWITTERIONIC PIPERAZINE (TVZ-7) IN CLINICAL CANCER, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(5), 1997, pp. 351-353

Authors: BIALKOWSKI MM WIERZBICKI JG PORTER AT
Citation: Mm. Bialkowski et al., MODELING OF INTERNAL DOSE DISTRIBUTIONS DURING SR-89 TREATMENT OF A PATIENT WITH BONE METASTASES, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(5), 1997, pp. 355-362

Authors: DILLMAN RO
Citation: Ro. Dillman, MAGIC BULLETS AT LAST - FINALLY - APPROVAL OF A MONOCLONAL-ANTIBODY FOR THE TREATMENT OF CANCER, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 223-225

Authors: ORDER SE
Citation: Se. Order, A NEW TECHNIQUE FOR THE 21ST-CENTURY - OUTPATIENT, HIGH-DOSE, TUMOR SELECTIVE, IRRADIATION BY INFUSION, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 227-227

Authors: DILLMAN RO CRISPIN R OLDHAM RK
Citation: Ro. Dillman et al., THE CANCER-BIOTHERAPY-RESEARCH-GROUP [CBRG], FORMERLY THE NATIONAL-BIOTHERAPY-STUDY-GROUP [NBSG] - A 10-YEAR PERSPECTIVE, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 229-242

Authors: DILLMAN RO CHURCH C BARTH NM OLDHAM RK WIEMANN MC
Citation: Ro. Dillman et al., LONG-TERM SURVIVAL AFTER CONTINUOUS-INFUSION INTERLEUKIN-2, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 243-248

Authors: DILLMAN RO WIEMANN MC VANDERMOLEN LA BURY MJ DEPRIEST C CHURCH C
Citation: Ro. Dillman et al., HYBRID HIGH-DOSE BOLUS CONTINUOUS-INFUSION INTERLEUKIN-2 IN PATIENTS WITH METASTATIC MELANOMA - A PHASE-II TRIAL OF THE CANCER-BIOTHERAPY-RESEARCH-GROUP (FORMERLY THE NATIONAL-BIOTHERAPY-STUDY-GROUP), CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 249-255

Authors: PELLEGRINI P BERGHELLA AM DELBEATO T MACCARONE D CENCIONI S ADORNO D CASCIANI CU
Citation: P. Pellegrini et al., THE SCEA MOLECULE SUPPRESSIVE ROLE IN NK AND TH1 CELL FUNCTIONS IN COLORECTAL-CANCER, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 257-264

Authors: BERGHELLA AM PELLEGRINI P DELBEATO T ADORNO D CASCIANI CU
Citation: Am. Berghella et al., IL-10 AND SIL-2R SERUM LEVELS AS POSSIBLE PERIPHERAL-BLOOD PROGNOSTICMARKERS IN THE PASSAGE FROM ADENOMA TO COLORECTAL-CANCER, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 265-272

Authors: KAMEI H KOIDE T HASHIMOTO Y KOJIMA T HASEGAWA M UMEDA T
Citation: H. Kamei et al., EFFECT OF ALLOMELANIN ON TUMOR-GROWTH SUPPRESSION IN-VIVO AND ON THE CELL-CYCLE PHASE, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 273-276
Risultati: 1-25 | 26-50 | 51-57